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A B S T R A C T
Background: Hereditary angioedema due to C1 inhibitor deﬁciency (C1-INH-HAE) causes swelling in the
skin and upper airways and pain in the abdomen because of mucosal swelling. C1-INH-HAE is frequently
misdiagnosed, leading to delays in diagnosis, inadequate treatment, and unnecessary procedures.
Objective: Toevaluate thehistoryofmisdiagnosis inpatientsparticipating in the IcatibantOutcomeSurvey (IOS).
Methods: The IOS is an observational study in which safety and effectiveness of icatibant have been eval-
uated since 2009. As part of the IOS, patients record any misdiagnoses received before being diagnosed as
having C1-INH-HAE.
Results: In January 2016, a total of 418 of 633 IOS patients with C1-INH-HAE type I or II had provided
misdiagnosis data. Of these, 185 of 418 (44.3%) received 1 or more prior misdiagnoses. The most common
misdiagnoses were allergic angioedema (103 of 185) and appendicitis (50 of 185). A variety of other mis-
diagnoses were reported, including a substantial number of gastrointestinal disorders (excluding appendi-
citis). Misdiagnosis rates were similar between males (41.1%) and females (46.5%) and between C1-INH-HAE
type I (43.7%) and type II (51.6%). Patients with family members diagnosed as having C1-INH-HAE were
signiﬁcantly less likely to be misdiagnosed than patients without a family history (140 of 366 [41.7%] vs 38
of 58 [65.5%], respectively; P ¼ .001). Patients with a prior misdiagnosis had longer median delay to C1-INH-
HAE diagnosis (13.3 years) than patients without (1.7 years; P < .001).
Conclusion: From this large database, approximately 50% of patients with C1-INH-HAE type I or II have
previously had their conditions misdiagnosed, most commonly as allergic angioedema or appendicitis.
Misdiagnosis results in marked delays in receiving the correct diagnosis, during which time patients cannot
access effective, lifesaving treatment.
Trial Registration: ClinicalTrials.gov: NCT01034969.
 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Hereditary angioedema due to C1 inhibitor deﬁciency (C1-INH-
HAE) is a rare autosomal dominant condition that causes recurrent
episodic edema without wheals of the skin, abdomen, and upper
airways, which can lead to fatal obstruction.1e6 Two phenotypic
variants of C1-INH-HAE have been described: type I, in which
antigenic and functional plasma C1-INH levels are below normal
range, and type II, in which antigenic C1-INH levels are normal
but functional C1-INH levels are below normal.4 This disease is
estimated to occur in approximately 1 in 50,000 individuals
worldwide. C1-INH-HAE has substantial variability in disease
manifestations, and symptoms such as swelling and pain can
overlap with other more common allergic and gastrointestinal
conditions. A low clinical suspicion for C1-INH-HAE, particularly
among physicians not familiar with C1-INH-HAE, can lead to mis-
diagnosis.3,7e10 Incorrect diagnoses range from allergies to systemic
lupus erythematosus, with a variety of treatments, including
antihistamines, corticosteroids, and other immunosuppressive
therapies,7,11e13 which can have adverse effects and are of limited
clinical utility.6,12,14e17 Patients with C1-INH-HAE typically experi-
ence more than a 10-year delay in diagnosis,11 and delays in
reaching a correct diagnosis can have signiﬁcant consequences for
the patient, particularly if the edema involves the laryngeal tissues
with an associated increased risk of suffocation.6
The issue of misdiagnosis and its consequences has been pre-
viously explored in case studies, post hoc medical record reviews,
and country-speciﬁc patient registries.11,12,14,16 To better charac-
terize this issue, the clinical aspects and trends of C1-INH-HAE
misdiagnosis need to be investigated within a large, diverse,
multinational, real-world patient population. The Icatibant
Outcome Survey (IOS) (ClinicalTrials.gov Identiﬁer: NCT01034969)
is an ongoing, Shire-sponsored, international, prospective, obser-
vational registry that collects demographic, medical history, and
clinical outcomes data in patients eligible for treatment with
icatibant, a subcutaneously administered bradykinin B2 receptor
antagonist, in the treatment of C1-INH-HAE.18,19 Analyses of data
from patients participating in the IOS were conducted to help
determine trends in C1-INH-HAE misdiagnosis.
Methods
The IOS observational registry, initiated in 2009, is being
conducted at 50 participating sites in 11 countries (Austria,
Brazil, Denmark, France, Germany, Greece, Israel, Italy, Spain,
Sweden, and the United Kingdom) to monitor the safety and
effectiveness of icatibant. All patients provide written informed
consent before participating in the IOS, and each participating
study site operates in accordance with local ethics committees
and/or health authorities, the Declaration of Helsinki, and the
International Conference on Harmonisation Good Clinical Prac-
tice guidelines.
Patients with a diagnosis of C1-INH-HAE (type I or II), clinically
conﬁrmed by laboratory tests (C1-INH concentration and function),
who were receiving or were a candidate for icatibant treatment
were included in this analysis. Patients attended regular follow-up
visits, recommended every 6 months according to physician
routine clinical practice. Data were collected from electronic forms
completed by physicians during routine patient visits. Additional
details of the IOS registry have been previously described.20
At enrollment, patients reported any misdiagnoses (based on
HAE symptoms) received before the diagnosis of C1-INH-HAE.
Descriptive retrospective analyses of any reported misdiagnosis
were performed using the IOS data collected from July 2009
to January 2016. Descriptive statistics were used to compare
patients who had 1 or more misdiagnoses with patients who had
no misdiagnoses. Statistical testing was considered exploratory in
this observational study and no adjustment for multiplicity was
performed. Patients with a previous misdiagnosis also were
compared by type of misdiagnosis, C1-INH-HAE type I or II, sex
distribution, and familial history of C1-INH-HAE using descriptive
statistics. The Wilcoxon-Mann-Whitney test was used to
compare continuous variables. A c2 test was used for compari-
sons between categories, with a statistical signiﬁcance level of
a ¼ 0.05.
Results
Frequent Misdiagnosis of C1-INH-HAE
As of January 2016, a total of 633 patients with C1-INH-HAE
(type I or II) were enrolled in the IOS. Of these, 418 patients
(66.0%) had provided misdiagnosis data. Almost half of these
patients (185 of 418 [44.3%]) had received 1 or more misdiagnoses
before being diagnosed as having C1-INH-HAE, whereas 223 of
418 (55.7%) had never had a misdiagnosis. Patients with and
without a prior misdiagnosis had similar demographics for sex,
C1-INH-HAE diagnosis (type I or II), ethnicity, and age at symptom
onset (Table 1). Patients with 1 or more misdiagnoses were
signiﬁcantly older at the time of correct diagnosis (median age,
28.4 years; range, 3.8e77.3 years) than those without a misdiag-
nosis (median age, 16.7 years; range, 0.0e77.3 years; P < .001).
Patients with family members with C1-INH-HAE were signiﬁcantly
less likely to receive an initial misdiagnosis compared with those
without familial C1-INH-HAE (140 of 336 [41.6%] vs 38 of 58
[65.5%]; P < .001) (Table 2). The overall country-speciﬁc rate of
C1-INH-HAE misdiagnosis from IOS patients is given in Table 3,
Table 1
Patient Characteristics in Those With and Without a Prior HAE Misdiagnosis
Characteristic Patients with 1
misdiagnoses (n ¼ 185)
Patients without a
misdiagnosis (n ¼ 233)
Age at enrollment, mean (SD)
[range], y
43.4 (14.2) [1.0e81.6] 38.5 (15.2) [1.0e81.8]
Female, No. (%) 113 (61.1) 130 (55.8)
Ethnicity, No. (%)a
White 174 (95.1) 220 (95.7)
Asian 5 (2.7) 4 (1.7)
Other 4 (2.2) 6 (2.6)
C1-INH-HAE diagnosis, No. (%)
Type I 169 (91.4) 218 (93.6)
Type II 16 (8.6) 15 (6.4)
Age at symptom onset,
mean (SD) [range], yb
14.0 (11.2) [0.1e67.0] 12.9 (11.8) [0.3e77.0]
Age at diagnosis, mean (SD)
[range], yc
29.0 (14.7) [3.8e77.3] 20.4 (15.7) [0e77.3]
Time from symptom onset to
C1-INH-HAE diagnosis,
mean (SD) [median], yd
15.0 (13.4) [13.3] 7.0 (13.2) [1.7]
No. of attacks per year,
mean (SD) [median]
18.9 (21.2) [10.7] 18.9 (27.6) [7.2]
Frequency of attacks per year,
No. (%)e
<10 attacks per year 82 (48.8) 123 (56.7)
10 attacks per year 86 (51.2) 94 (43.3)
Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deﬁciency;
HAE, hereditary angioedema.
aData reported for 183 patients with 1 or more misdiagnoses and 230 patients
without a misdiagnosis.
bData reported for 177 patients with 1 or more misdiagnoses and 204 patients
without a misdiagnosis.
cData reported for 183 patients with 1 or more misdiagnoses and 220 patients
without a misdiagnosis.
dData reported for 176 patients with 1 or more misdiagnoses and 198 patients
without a misdiagnosis.
eData reported for 168 patients with 1 or more misdiagnoses and 217 patients
without a misdiagnosis.
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and C1-INH-HAE misdiagnosis by decade of patient birth is given
in Table 4.
Allergic Angioedema and Appendicitis Misdiagnoses
In patients who reported 1 or more misdiagnoses (Fig 1), the
most common diagnoses were allergic angioedema (103 of 185
[55.7%]) and appendicitis (50 of 185 [27.0%]). Misdiagnoses were
reported by 169 of 387 patients with C1-INH-HAE type I (43.7%)
and by 16 of 31 patients with type II (51.6%) (P ¼ .39). The per-
centage of patients reporting each misdiagnosis type was similar
between both C1-INH-HAE types (Fig 2).
The percentages of patients who reported 1 or more mis-
diagnoses were not statistically different between males (72 of 175
[41.1%]) and females (113 of 243 [46.5%]) (P ¼ .28). Similarly, the
types of misdiagnosis were not different between males and
females (Fig 3).
Substantial Delays in Receiving the Correct Diagnosis
Patients with C1-INH-HAE who had a prior misdiagnosis expe-
rienced a signiﬁcantly longer delay from symptom onset to C1-INH-
HAE diagnosis (median, 13.3 years; range, 13.5 to 67.3 years) than
patients without (median, 1.7 years; range, 41.8 to 66.9 years;
P < .001). Misdiagnoses of nonallergic angioedema and biliary
disorder resulted in the greatest mean time from symptoms to
C1-INH-HAE diagnosis (Table 5).
Discussion
This study found that patients with C1-INH-HAE commonly
receive misdiagnoses, frequently allergic angioedema or appendi-
citis. The present analysis is the ﬁrst using IOS data to show that an
initial misdiagnosis is a major driver of the long delays that patients
Table 2
Patient Misdiagnosis by Family History of HAE
Previous misdiagnosis No. (%) of patients with family history of HAE
Yes No
Yes 140 (41.7) 38 (65.5)
No 196 (58.3) 20 (34.5)
Totala 336 58
Abbreviation: HAE, hereditary angioedema.
aData available for both family history and misdiagnosis; missing or unknown data
were excluded.
Table 3
Country-Speciﬁc Rate of C1-INH-HAE Misdiagnosis From IOS Patientsa
IOS country No. (%) of patients with 1
misdiagnoses (n ¼ 185)
No. (%) of patients without
a misdiagnosis (n ¼ 233)
Austria 11 (84.6) 2 (15.4)
Brazil 16 (84.2) 3 (15.8)
Denmark 15 (68.2) 7 (31.8)
Greece 12 (63.2) 7 (36.8)
Italy 28 (46.7) 32 (53.3)
United Kingdom 26 (46.4) 30 (53.6)
Israel 22 (41.5) 31 (58.5)
Germany 27 (35.5) 49 (64.5)
France 6 (28.6) 15 (71.4)
Spain 22 (28.6) 55 (71.4)
Sweden 0 (0.0) 2 (100.0)
Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deﬁciency;
IOS, Icatibant Outcome Survey.
aThe numbers of patients by country with missing misdiagnosis data are as follows:
France, n¼ 182; Germany, n¼ 11; United Kingdom, n¼ 8; Spain, n¼ 7; Israel, n¼ 4;
Denmark, n ¼ 2; and Italy, n ¼ 1. Ta
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with C1-INH-HAE can experience before a correct diagnosis of
C1-INH-HAE is made.
It is well recognized that patients with C1-INH-HAE can be
subject to an initial misdiagnosis, but analyses of misdiagnosis
patterns and trends in a real-world setting are scarce.4,5 The rarity
of C1-INH-HAE, heterogeneity of its affected population, and the
overlap in symptoms with other more common diseases, such as
allergic angioedema and appendicitis, make diagnosing C1-INH-
HAE challenging.3,7e9 Moreover, angioedema is a widely variable
disease with different types and subtypes, including acquired
angioedema and idiopathic histaminergic angioedema.4,5 It is
understandable, therefore, that clinical suspicion for C1-INH-HAE
may be low, particularly among physicians who are not familiar
with the disorder or its clinical management.
Our ﬁndings suggest that C1-INH-HAE misdiagnoses are not
inﬂuenced by patient sex or HAE type (I vs II). A numerically higher
percentage of males were diagnosed as having other nonallergic
angioedema (P ¼ .12); however, the broad range of misdiagnoses in
this categoryand the relatively small numberof patients prevent any
substantial conclusions by sex. Patients with a family history of
C1-INH-HAE were signiﬁcantly less likely to receive misdiagnoses,
most likely because of consideration of positive family history in the
differential diagnosis. Physician awareness that in 25% of C1-INH-
HAE cases there is no positive family history may help decrease
misdiagnoses.21 Nevertheless, it is remarkable that almost half of
patientswitha family historyof C1-INH-HAE receivedmisdiagnoses.
This ﬁnding could represent an opportunity to improve diagnosis
by encouraging family members to come forward for diagnosis and
by facilitating diagnosis by primary care physicians. Geographic re-
gion could potentially play a part in misdiagnosis rates, although
similarly, the small number of patients with misdiagnosis data
in each of the 11 countries precludes meaningful comparison.
Patients with C1-INH-HAE may present with abdominal pain,
which is reﬂected in the range of gastrointestinal diagnoses patients
in the current study report as being their initial diagnosis. Impor-
tantly, angioedema that affects viscera or bowel is not necessarily
associated with visible swelling, making a high index of suspicion
and careful history taking that includes questions about peripheral
or laryngeal swelling essential for a diagnosis of angioedema.16,22
In addition, patients with 1 or moremisdiagnoses experienced a
signiﬁcantly longer delay that those without a misdiagnosis before
receiving a correct C1-INH-HAE diagnosis. A 2013 analysis of IOS
data found a median diagnostic delay in patients with C1-INH-HAE
type I or II across 8 European countries of 8.5 years (range, 0e62.0
years)8; however, that analysis, unlike the present study, did not
account for prior misdiagnosis. Given that the age of symptom
onset in the present study is similar in both groups and those who
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Figure 1. Percentage of patients with hereditary angioedema due to C1 inhibitor
deﬁciency (C1-INH-HAE) by misdiagnosis (n ¼ 185). Patients may have reported
more than 1 misdiagnosis. For other misdiagnoses, see Table 5. GERD indicates
gastroesophageal reﬂux disease.
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Figure 2. Percentage of patients with hereditary angioedema due to C1 inhibitor
deﬁciency (C1-INH-HAE) by misdiagnosis according to C1-INH-HAE type I or II.
Patients may have reported more than 1 misdiagnosis. For other misdiagnoses, see
Table 5. GERD indicates gastroesophageal reﬂux disease.
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Figure 3. Percentage of patients with hereditary angioedema due to C1 inhibitor
deﬁciency (C1-INH-HAE) by misdiagnosis according to sex. Patients may have re-
ported more than 1 misdiagnosis. For other misdiagnoses, see Table 5. GERD in-
dicates gastroesophageal reﬂux disease.
Table 5
Time (in Years) From First Symptoms to C1-INH-HAE Diagnosis by Type of Prior
Misdiagnosis in 185 Patients
Prior misdiagnosis Time from ﬁrst symptoms to misdiagnosis, y
Mean (SD) Median (range)
Allergic angioedema (n ¼ 97) 15.5 (13.9) 14.8 (13.5 to 67.3)
Appendicitis (n ¼ 47) 13.3 (13.8) 12.0 (1.2 to 67.3)
Othera (n ¼ 40) 15.1 (12.0) 13.3 (0.4 to 46.2)
Nonallergic angioedema (n ¼ 38) 18.0 (14.0) 15.7 (1.2 to 56.6)
Biliary disorder (n ¼ 10) 16.0 (10.9) 15.8 (0.0 to 34.4)
GERD (n ¼ 8) 16.1 (11.1) 14.4 (0.4 to 34.4)
Peptic ulcer (n ¼ 7) 18.2 (19.7) 13.4 (0.4 to 54.0)
Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deﬁciency;
GERD, gastroesophageal reﬂux disease.
aOther diagnoses as reported by patients include colic, colic (gastroenteritis), edema
after trauma, endometriosis, familial Mediterranean fever, indigestion, leukemia,
rheuma, tonsillitis, urinary tract infection, urticaria, acetonemic vomiting, allergy,
bowel obstruction, cardia/neoplasia, colitis, constipation, diverticulitis, dubious ﬂuid
in abdomen, gastroenteritis, heartburn, Helicobacter pylori, irritable bowel disease,
irritable colon, kidney problem, orchitis (acute gastroenteritis), pancreatitis,
psychological overstress syndrome, skin and kidney disorder, stress (acute gastro-
enteritis), and urticaria (tonsillitis). Patients could have reported more than 1
misdiagnosis.
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had a misdiagnosis tended to be older when C1-INH-HAE was
correctly diagnosed, this delay can be attributed to the initial
misdiagnosis. An initial misdiagnosis can have practical conse-
quences for patients with C1-INH-HAE that can range from
increased risk of death from laryngeal edema6 to altering the
treatment approach of subsequent health care professionals, delay
of effective therapy, and prolonged issues associated with an
otherwise manageable condition. Patients with misdiagnoses
included those with frequent attacks. Given the age at onset of
symptoms, delay in diagnosis is likely to lead to severe disruption of
education and early working life and may account for many of the
economic, social, and psychological consequences of C1-INH-HAE
described elsewhere.23e27 In a recent study by Bygum et al,24
misdiagnosis was mentioned by patients as an important burden
of their disease and was included in a conceptual model of C1-INH-
HAE burden in patients.
Considering that published data regarding C1-INH-HAE misdi-
agnosis are scarce and consist largely of case reports and country-
speciﬁc analyses, the relatively large real-world multinational
database used in this analysis substantially contributes to the
understanding of this issue. Limitations of this analysis necessarily
include those related to patient recall, the number of patients
analyzed, and the fact that the IOS currently includes only patients
from centers in Europe, South America, and the Middle East. Recent
evidence from Japan, however, suggests that patients with HAE in
non-IOS countries also experience long delays in diagnosis and
similar rates of misdiagnosis.28
Awareness of C1-INH-HAE has increased in recent years; how-
ever, patients continue to experience misdiagnoses, resulting in
unnecessary treatment, delays in appropriate diagnosis and ther-
apy, and increased risk of death.6 Increased awareness of C1-INH-
HAE signs, symptoms, and prodromes,29 the types of common
C1-INH-HAE misdiagnoses, knowledge of C1-INH-HAE occurrence
in the absence of a positive family history, andwide availability of C4
blood test screening, with C1-INH testing if suspicion is high, may
assist physicians and patients in recognizing C1-INH-HAE as a
possible cause of symptoms and encourage testing to conﬁrmor rule
out C1-INH-HAE. Ongoing education for physicians who are most
likely to encounter patients with C1-INH-HAE may reduce misdi-
agnosis and the delay in receiving a correct diagnosis and treatment.
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